181 related articles for article (PubMed ID: 31452441)
1. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.
Bullock M; Lim G; Zhu Y; Åberg H; Kurdyukov S; Clifton-Bligh R
Thyroid; 2019 Nov; 29(11):1623-1633. PubMed ID: 31452441
[No Abstract] [Full Text] [Related]
2. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
3. Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT.
Bullock M; Lim G; Li C; Choi IH; Kochhar S; Liddle C; Zhang L; Clifton-Bligh RJ
Oncotarget; 2016 Dec; 7(52):85948-85962. PubMed ID: 27852061
[TBL] [Abstract][Full Text] [Related]
4. ETS variant transcription factor 5 and c-Myc cooperate in derepressing the human telomerase gene promoter via composite ETS/E-box motifs.
Zhang F; Wang S; Zhu J
J Biol Chem; 2020 Jul; 295(29):10062-10075. PubMed ID: 32518154
[TBL] [Abstract][Full Text] [Related]
5. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
[TBL] [Abstract][Full Text] [Related]
6. The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.
Puli OR; Danysh BP; McBeath E; Sinha DK; Hoang NM; Powell RT; Danysh HE; Cabanillas ME; Cote GJ; Hofmann MC
Neoplasia; 2018 Nov; 20(11):1121-1134. PubMed ID: 30265861
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
8. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
[TBL] [Abstract][Full Text] [Related]
10. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway.
Maida Y; Kyo S; Kanaya T; Wang Z; Yatabe N; Tanaka M; Nakamura M; Ohmichi M; Gotoh N; Murakami S; Inoue M
Oncogene; 2002 Jun; 21(26):4071-9. PubMed ID: 12037663
[TBL] [Abstract][Full Text] [Related]
11. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
12. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
[TBL] [Abstract][Full Text] [Related]
13. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of
Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
[No Abstract] [Full Text] [Related]
15. EWS/ETS fusions activate telomerase in Ewing's tumors.
Takahashi A; Higashino F; Aoyagi M; Yoshida K; Itoh M; Kyo S; Ohno T; Taira T; Ariga H; Nakajima K; Hatta M; Kobayashi M; Sano H; Kohgo T; Shindoh M
Cancer Res; 2003 Dec; 63(23):8338-44. PubMed ID: 14678994
[TBL] [Abstract][Full Text] [Related]
16. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.
Stern JL; Hibshman G; Hu K; Ferrara SE; Costello JC; Kim W; Tamayo P; Cech TR; Huang FW
Mol Cancer Res; 2020 Jul; 18(7):1050-1062. PubMed ID: 32276990
[TBL] [Abstract][Full Text] [Related]
18. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF
Gabler L; Lötsch D; Kirchhofer D; van Schoonhoven S; Schmidt HM; Mayr L; Pirker C; Neumayer K; Dinhof C; Kastler L; Azizi AA; Dorfer C; Czech T; Haberler C; Peyrl A; Kumar R; Slavc I; Spiegl-Kreinecker S; Gojo J; Berger W
Acta Neuropathol Commun; 2019 Aug; 7(1):128. PubMed ID: 31391125
[TBL] [Abstract][Full Text] [Related]
19. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
Liu R; Zhang T; Zhu G; Xing M
Nat Commun; 2018 Feb; 9(1):579. PubMed ID: 29422527
[TBL] [Abstract][Full Text] [Related]
20. GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer.
McKinney AM; Mathur R; Stevers NO; Molinaro AM; Chang SM; Phillips JJ; Costello JF
Cell Rep; 2022 Sep; 40(12):111344. PubMed ID: 36130485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
